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Abstract
Background: Cerebellar ataxia represents a rare and severe complication of Sjӧgren syndrome (SS), especially with
a progressive onset and cerebellar atrophy on imaging.
Case presentation: We report the case of a 30-year-old woman, with a past history of dry eyes and mouth,
who presented a severe cerebellar ataxia worsening over 4 years associated with tremor of the limbs and the
head. Brain MRI showed bilateral hyperintensities on T2 and FLAIR sequences, affecting periventricular white
matter, with marked cerebellar atrophy. Complementary investigations confirmed the diagnosis of primary SS
(pSS). The patient was treated by methylprednisolone, Cyclophosphamid and Azathioprine. Her clinical and
radiological states are stabilized after 2 years of following. Primary cerebellar degeneration is extremely rarely
associated with pSS. Few cases of isolated cerebellar ataxia or belonging to a multifocal disease were reported
in the literature, most of them characterized by an acute or rapidly progressive onset. Cerebellar atrophy was
described in only three patients. There have been few clarifications of the pathogenesis of the neurological
manifestations in pSS. Treatment is based on corticosteroids and immunosuppressive agents with no
consensus of a specific therapy.
Conclusions: Cerebellar ataxia due to pSS may exceptionally mimic a degenerative cerebellar ataxia, especially
when the onset is progressive, which represents the particularity of our observation. The role of brain MRI and
antibodies remains important for the differential diagnosis.
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Background
Sjögren syndrome (SS) is a chronic autoimmune disease
involving mainly salivary and lacrimal glands, characte-
rized by mononuclear cell infiltration of the exocrine
glands, which leads to typical xerophtalmia and xeros-
tomia. Neurological manifestations occur in approxi-
mately 20 % of patients [1–4]. Since peripheral nervous
system’s (PNS) involvement has been widely described,
several studies reported variable prevalence of central
nervous system (CNS) manifestations ranging from
2.5 and 60 % of all primary SS (pSS) patients [1, 5, 6].
Although ataxia due to pSS has also been described
[7–10], marked cerebellar atrophy associated with
pSS has rarely been reported. We report the case of
a 30-year-old woman who presented a progressive
cerebellar syndrome with marked cerebellar atrophy
on imaging revealing a pSS.
Case report
A 40-year-old Tunisian female, without any past history
of dysimmune disorder or arthralgia, developed progres-
sive unsteadiness of gait worsening over 4 years. She had
no familial history of gait disturbance. She complains
also about tremor of limbs and head appearing since
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1 year. On initial neurological examination, she was
unable to walk, with a severe cerebellar syndrome
including dysarthria and ataxia of four limbs and trunk.
Motor power and sensory examinations were normal.
Her deep-tendon reflexes were normoactive, and her
plantar responses were flexor bilaterally. Bilateral rest
and intention tremor of the four limbs and head was
also noticed. She had no nystagmus, no bladder dysfunc-
tion, no parkinsonism and no cognitive impairment.
General examination was otherwise normal. During
her hospitalization, she complained about dry eyes and
mouth.
Complete blood count, serum electrolytes, creatinine,
glucose, coagulation tests, liver functional tests, lacti-
codeshydrogenase, blood sedimentation rate, lipids, and
creatine kinase were normal.
Brain magnetic resonance imaging (MRI) showed
bilateral hyperintensities on T2 and FLAIR sequences,
affecting periventricular white matter, predominantly in
the subcortical white matter. No gadolinium enhance-
ment was found (Fig. 1). Marked cerebellar atrophy
without signal abnormalities was notified (Fig. 2). Spinal
MRI was normal. Visual evoked potential and electro-
myography were both normal. Toxic causes of cerebellar
ataxia were ruled out by the interrogatory.
The cerebrospinal fluid contained 01 cell/ mm3 and
70 mg/dl of protein, and the glucose level was not
decreased. There was no oligoclonal bands. Laboratory
tests were positive for anti-Ro-SSA antibodies. Anti-
nuclear antibodies were slightly positive (1/100) and
speckled on immunofluorescence, DNA antibodies were
negative. Assays for ss-B (anti-La), anti-phospholipids
(cardiolipin and β2 glycoprotein), anti-nuclear ribonucleo-
protein (RNP), anti-Smith (Sm), anti-histone, anti PM-Scl,
anti-PCNA, anti-Scl70, anti-centromere, anti-Jo1, anti-
ribosomal and anti-nucleosome antibodies were all
negative. Rheumatoid factor was also negative. HIV and
hepatitis tests were negative. Paraneoplasic antibodies
(anti-Hu, anti-Ri, anti-Yo, anti-PNMa2 and anti-CRMP5),
anti-GAD, anti-gliadin, anti-transglutaminase, anti-thyro
globulin and anti-thyroid peroxidase antibodies were
not detected. Anti-VGCC antibodies were not tested.
The break up time test confirms the xerophtalmia.
Salivary glands biopsy was not performed because of
the important head tremor. The diagnosis of pSS with
neurological complications was retained according to
the 2002 American European classification criteria [11].
Genetic tests for Friedreich ataxia and ataxia with
vitamin E deficiency were negative.
The patient was treated by intravenous methylpredni-
solone (1 g/day), administered for 5 days followed by
maintenance therapy with oral methylprednisolone
(1 mg/kg/day) continued for 3 months, and then pro-
gressively decreased. She received Cyclophosphamid
once per month for 6 months. Normocardil (60 mg/day)
and Meprobamate (600 mg/day) were also administered
for tremor. There was no significant clinical improve-
ment, but her state did not worsened after 2 years of
follow up. A second brain MRI, made 3 months after
she received sixth dose of Cyclophosphamid, showed the
same stable lesions.
Discussion
In contrast to the uniform features of the PNS complica-
tions of pSS, CNS abnormalities are associated with a
much wider spectrum of manifestations. In the largest
cohort of 431 pSS patients published in 2010, the most
frequent picture of CNS involvement was a recurrent
subacute encephalopathy characterized by memory loss,
cognitive dysfunction, visual disturbances and dizziness
[7]. The first description of cerebellar syndrome in asso-
ciation with pSS was by Attwood and Poser in 1961 [12].
Fig. 1 Brain MRI FLAIR sequences showing bilateral hyperintensities, affecting periventricular regions predominantly in the subcortical white matter
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Since then, few cases of isolated cerebellar ataxia or
belonging to a multifocal disease were reported in the
literature, most of them characterized by an acute or
rapidly progressive onset [7–10, 13].
Primary cerebellar degeneration is extremely rarely
associated with pSS. There are few reports of cerebellar
degeneration associated with different autoimmune
diseases, especially with systemic lupus erythematous
[14, 15], and Neuro-Behçet’s disease [16, 17]. To our
knowledge, only three cases of pSS causing cerebellar
atrophy have been reported [9, 18, 19], two of them
having positive neuronal antibodies [9, 18]. The first case
of cerebellar ataxia with cerebellar atrophy and negative
neuronal antibodies was reported by Kim et al. in
2012 [19]. The patient was a 46-year-old woman who
presented a rapidly progressive onset ataxia 3 months
before her first examination. She had isolated cerebellar
syndrome, marked cerebellar atrophy with an enlarged
fourth ventricle and cisterna magna on brain MRI, but
without any signal abnormalities on cerebral or cerebellar
parenchyma. Brain PET revealed decreased glucose
metabolism in the bilateral cerebellum. However, our
patient exhibited progressive onset (4 years before exa-
mination), associated rest and intention tremor, and
multiple white matter hyperintensities in subcortical and
periventricular areas on imaging. In the two cases, there
was no significant improvement by treatment.
Movement disorders have been rarely described in
association with pSS, and are less classic that in systemic
lupus erythematous. There are few reports of chorea,
dystonia, athetosis and tremor [20]. Extrapyramidal
syndrome has been more frequently reported [21–24].
There have been few clarifications of the pathogenesis
of the neurological manifestations in pSS. In PNS
involvement, vasculitis and perivascular cell invasion are
the most common findings [25, 26]. Some reports have
also described the same mechanism in CNS pathology
of SS, with subsiding angitis and necrotising vasculitis
of small vessels [27–29]. Interestingly, other reports
suggested a nonvasculitic pathological mechanism of
the CNS damage in SS [30–33]. The latest autopsy
case published by Yaguchi et al. in 2008 was about a
40-year-old woman diagnosed with an acute encepha-
lomyelopathy due to a pSS. Neuropathological exami-
nation revealed multifocal lesions in the cervical spinal
cord and medulla, along with scattered perivascular
lymphocytic infiltration. In addition, there was demyeli-
nation, spongy change and axonal swelling in the white
matter, but no remarkable vasculitic changes were seen in
the CNS [34].
This observation confirms the possibility that the main
pathological mechanism of CNS damage in SS is not
necessarily related to vasculitis. Axonal degeneration,
necrotic lesions and perivascular lymphocytic cuffing
may explain the non-response to corticosteroid treat-
ment with a fatal evolution in some cases.
The course of the disease of neuro-Sjogren can be
MS-like with relapsing-remitting modality [1, 7], or
progressive such the case of our patient. In Massara’s
paper, it was proved that CNS involvement may even
precede clinical diagnosis of SS by many years, with
patients misdiagnosed as multiple sclerosis (MS) fulfilling
the diagnosis criteria [7].
To date, there is no consensus of a specific therapy the
management of Sjögren’s syndrome with CNS involve-
ment. Many kinds of treatments have been used inclu-
ding steroids, immunoglobulins, plasmapheresis, and
D-penicillamine [21, 25, 35–37]. Our patient was treated
Fig. 2 Brain MRI T2 sequences showing marked cerebellar atrophy with an enlarged fourth ventricle and cisterna magna, without signal
abnormities of the cerebellum
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by high doses of methylprednisolone associated with
Cyclophosphamid without improvement but also no
worseness in her neurological abnormalities.
Conclusion
Cerebellar ataxia represents a rare and severe compli-
cation of pSS. It also represents a diagnostic challenge
for the clinician especially when preceding the classic
glandular symptoms of the disease, fact that may delay
the recognition of SS and heavily affect the outcome.
The differential diagnosis between pSS with CNS
involvement and classical MS may be sometimes very
difficult. The clinician must follow the course of the
disease, repeating the look for clinical manifestations
and laboratory tests which orient to this particular
diagnosis. Cerebellar ataxia due to pSS may exceptio-
nally mimic a degenerative cerebellar ataxia, especially
when the onset is progressive, which represents the
particularity of our observation. The role of brain MRI
and antibodies remains important for the differential
diagnosis.
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